Matching Swiss venture capital with Swedish life science companies

An initiative by Invest Sweden and Swedish Trade Council

- in collaboration with Swedish Medtech, Swecare and Sweden Bio

Take the opportunity to get your company matched with major European VC investors

• A selected group/platform of some of the most interesting Life Science investors in Switzerland and Europe with interest in Swedish Life Science companies

- Novartis Venture Funds is one of the world’s largest corporate biotech venture funds managing MUSD 750

- HBM Partners is among the global leaders in Life Science-focused investing with USD 1 billion under management

- Red Alpine is active in early stage venture capital fund investing in Life Science and ICT with focus on e.g. Scandinavia

- BBBiotechVentures is a healthcare dedicated venture capital fund in the Bellevue Group (listed on the SIX Swiss Exchange)

• Access to key decision makers and dedicated feedback on your company

• Opportunity to get short listed for in-depth discussions with venture capital funds

What are the Swiss investors looking for?

• Drug development, biotech platforms, medtech/medical device, diagnostics, therapeutics

• From start-up/seed capital to late stage investments

- From R&D, clinical studies and human proof-of-concept trials to registration trials/marketing and businesses/growth capital

• Investment range MEUR 0.1-30

• Innovative and leading companies in their niche

How do I participate?

Register no later than June 28th trough the attached form or online at

www.swedishtrade.se/sv/calendarpage/matching-swiss-venture-capital-with-swedish-life-science-companies and you will be contacted by Invest Sweden or the Swedish Trade Council with further information.

Why Swiss Venture Capital? - Switzerland constitutes an interesting VC  pool

• Even in the current down turn Swiss VC investments in Life Science show steady volumes and actually increases relative other segments

• The VCs see a problem in the low "deal flow" i.e. a lack of interesting business ventures

• The Swiss VCs invest 90% of their capital (that is to a  relative high degree foreign capital) in European ventures

- Historically, however investments in Swedish entities have not been substantial

If you have any questions please contact:

Hampus Nilzén                                                                                     

hampus.nilzen (at) swedishtrade.se

+43 1 402 35 15 21

Peter Bramberg

peter.bramberg (at) investsweden.se

+46  8 402 78 45